Liquidia Corporation (LQDA)
NASDAQ: LQDA · Real-Time Price · USD
14.75
-0.34 (-2.25%)
At close: Mar 31, 2025, 4:00 PM
14.72
-0.03 (-0.18%)
After-hours: Mar 31, 2025, 7:30 PM EDT
Liquidia Revenue
In the year 2024, Liquidia had annual revenue of $14.00M, down -19.97%. Liquidia had revenue of $2.92M in the quarter ending December 31, 2024, a decrease of -35.62%.
Revenue (ttm)
$14.00M
Revenue Growth
-19.97%
P/S Ratio
82.95
Revenue / Employee
$82,329
Employees
170
Market Cap
1.26B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
LQDA News
- 3 days ago - Liquidia Corporation Announces FDA Acceptance of New Drug Application Resubmission for YUTREPIA™ (treprostinil) Inhalation Powder - GlobeNewsWire
- 12 days ago - Liquidia Corporation (LQDA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 12 days ago - Liquidia Corporation Reports Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 19 days ago - Liquidia Corporation to Report Full Year 2024 Financial Results on March 19, 2025 - GlobeNewsWire
- 4 months ago - Liquidia Corporation: Resilience In The Face Of Formidable Opposition Can Pay Off - Seeking Alpha
- 4 months ago - Liquidia Corporation (LQDA) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 4 months ago - Liquidia Corporation Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewsWire
- 6 months ago - United States Supreme Court Declines to Review Rulings that Invalidate United Therapeutics' Patent - GlobeNewsWire